Akero Therapeutics Begins Phase 3 Study on Efruxifermin for Liver Disease Treatment

6/11/24 7:05:07 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $AKRO alert in real time by email

Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced initiation of the SYNCHRONY Outcomes study, a Phase 3 trial evaluating the efficacy and safety of efruxifermin (EFX) in patients with compensated cirrhosis, fibrosis stage 4 (F4) due to metabolic dysfunction-associated steatohepatitis (MASH).

Get the next $AKRO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AKRO

Date	Price Target	Rating	Analyst
11/18/2024	$65.00	Buy	Citigroup
4/22/2024	$30.00	Neutral	BofA Securities
9/19/2023	$69.00	Overweight	Cantor Fitzgerald
8/28/2023	$83.00	Buy	UBS
1/27/2023	$40.00 → $65.00	Equal-Weight → Overweight	Morgan Stanley
9/14/2022	$10.00 → $50.00	In-line → Outperform	Evercore ISI
11/15/2021	$27.00 → $29.00	Equal-Weight	Morgan Stanley
11/15/2021	$64.00 → $62.00	Buy	HC Wainwright & Co.

More analyst ratings

$AKRO
Press Releases

Fastest customizable press release news feed in the world

Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024
-- Over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of three orthogonal measures: (1) ≥1-stage fibrosis improvement by NASH-CRN stage (conventional histopathology), (2) 30% reduction of liver stiffness by FibroScan® (imaging fibrosis biomarker), and (3) 0.5 point decrease in ELFTM score (serum fibrosis biomarker) – -- Analysis of biopsies by AI-based Digital Pathology (qFibrosis®, Histoindex) corroborated the extent of improvement in fibrosis observed with conventional histopathology after 24 and 96 weeks of EFX treatment, including statistically significant reductions in fibrosis within the perisinusoida
11/15/24 11:00:00 AM ET
$AKRO
Biotechnology: Pharmaceutical Preparations
Health Care
Akero Therapeutics to Present at the Jefferies London Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 12:00 p.m. GMT. A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website. About Akero TherapeuticsAkero Therapeutics is a c
11/13/24 4:05:00 PM ET
$AKRO
Biotechnology: Pharmaceutical Preparations
Health Care
Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
— First patients dosed in Phase 3 SYNCHRONY Outcomes study of lead candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to MASH — — Phase 3 SYNCHRONY Real-World and Histology studies on track to report results for their respective primary endpoints in 2026 and the first half of 2027 — — Phase 2b SYMMETRY study week 96 results expected to readout in February 2025 — SOUTH SAN FRANCISCO, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatiti
11/8/24 7:00:00 AM ET
$AKRO
Biotechnology: Pharmaceutical Preparations
Health Care

$AKRO
Financials

Live finance-specific insights

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
50mg (75%, p<0.001) and 28mg (46%, p=0.07) EFX groups demonstrated ≥1 stage improvement in fibrosis without worsening of MASH, approximately three- and two-fold the placebo rate (24%) 50mg (36%, p<0.01) and 28mg (31%, p<0.01) EFX groups demonstrated ≥2 stage improvement in fibrosis without worsening of MASH, more than 10-fold the placebo rate (3%) EFX-treated patients experienced statistically significant improvements on nearly all histological endpoints by ITT analysis as well as the primary analysis of patients with week 96 biopsies Investor webcast at 8:00 am ET Monday, March 4, 2024 SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics,
3/4/24 6:00:00 AM ET
$AKRO
Biotechnology: Pharmaceutical Preparations
Health Care
Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH
SOUTH SAN FRANCISCO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease, will hold an investor conference on Monday, March 4 at 8:00 a.m. ET to share results after 96 weeks of treatment for its HARMONY study, a double-blind, placebo-controlled Phase 2b study evaluating the efficacy of efruxifermin (EFX) in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), fibrosis stage 2 or 3 (F2-F3). Conference Call / Webcast DetailsThe company will host a conference call and webcast with slide presentation at 8:00 a.m. ET on Monday
2/29/24 8:00:00 AM ET
$AKRO
Biotechnology: Pharmaceutical Preparations
Health Care
Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins
22% (28mg EFX) and 24% (50mg EFX) of patients experienced at least a one-stage improvement in liver fibrosis with no worsening of NASH by week 36, compared to 14% for placebo 4% of patients in each EFX dose group experienced a three- or two-stage reversal of fibrosis with no worsening of NASH, compared to 0% for placebo 63% (28mg EFX) and 60% (50mg EFX) of patients experienced NASH resolution, representing statistically significant differences compared to 26% for placebo Investor webcast at 8:00 a.m. ET to further discuss data SOUTH SAN FRANCISCO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments
10/10/23 7:00:00 AM ET
$AKRO
Biotechnology: Pharmaceutical Preparations
Health Care

$AKRO
Leadership Updates

Live Leadership Updates

Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
-- Initiated Phase 3 SYNCHRONY Outcomes Trial of Lead Candidate Efruxifermin (EFX) in Patients with Compensated Cirrhosis (F4) Due to MASH -- Presented Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024 -- -- Leadership Team Expanded with Addition of Scott Gangloff as Chief Technical Officer -- SOUTH SAN FRANCISCO, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported second quarter financial results for the period ending June 30, 2024 and provided business updates. "The second
8/9/24 7:00:00 AM ET
$AKRO
Biotechnology: Pharmaceutical Preparations
Health Care
Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease, today announced the appointment of Scott Gangloff as Chief Technology Officer. "I am delighted to welcome Scott to Akero. His depth of experience leading drug manufacturing for both national and multi-national biopharmaceutical organizations enriches our company with an invaluable perspective during the late-stage clinical development of efruxifermin," remarked Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero. "The entire leadership team looks forward to
4/30/24 8:00:00 AM ET
$AKRO
Biotechnology: Pharmaceutical Preparations
Health Care
Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced the appointment of Patrick Lamy as Senior Vice President, Commercial Strategy. "Akero is thrilled to welcome Patrick to the team, especially following last year's HARMONY study results, which further demonstrate EFX's potential to treat NASH holistically and reverse fibrosis rapidly," said Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero. "Patrick's extensive experience in liver disease, and commercial stra
1/10/23 8:00:00 AM ET
$AKRO
Biotechnology: Pharmaceutical Preparations
Health Care

Akero Therapeutics Begins Phase 3 Study on Efruxifermin for Liver Disease Treatment

Chat with this insight

Recent Analyst Ratings for $AKRO

$AKRO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Development Officer Yale Catriona sold $251,274 worth of shares (9,061 units at $27.73) and exercised 9,061 shares at a strike of $21.10 (SEC Form 4)

Chief Development Officer Yale Catriona exercised 10,000 shares at a strike of $0.61 and sold $351,890 worth of shares (10,000 units at $35.19) (SEC Form 4)

Chief Operating Officer Young Jonathan exercised 40,716 shares at a strike of $21.09 and sold $1,601,252 worth of shares (50,716 units at $31.57), decreasing direct ownership by 4% to 216,286 units (SEC Form 4)

$AKRO Market Insights

Live Market Insights

This Analyst Sees Potential Downside In Eli Lilly, Adjusts Model For Acquired IPR&D Charges

Cantor Fitzgerald Reiterates Overweight on Akero Therapeutics

Cantor Fitzgerald Reiterates Overweight on Akero Therapeutics

$AKRO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Citigroup initiated coverage on Akero Therapeutics with a new price target

BofA Securities resumed coverage on Akero Therapeutics with a new price target

Cantor Fitzgerald initiated coverage on Akero Therapeutics with a new price target

$AKRO Press Releases

Fastest customizable press release news feed in the world

Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024

Akero Therapeutics to Present at the Jefferies London Healthcare Conference

Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

$AKRO SEC Filings

SEC Form 10-Q filed by Akero Therapeutics Inc.

SEC Form 8-K filed by Akero Therapeutics Inc.

SEC Form 10-Q filed by Akero Therapeutics Inc.

$AKRO Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Akero Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Akero Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Akero Therapeutics Inc.

$AKRO Financials

Live finance-specific insights

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH

Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins

$AKRO Leadership Updates

Live Leadership Updates

Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy

$AKRO Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Graham G. Walmsley bought $1,982,940 worth of shares (100,000 units at $19.83) (SEC Form 4)

Graham G. Walmsley bought $1,694,565 worth of shares (100,000 units at $16.95) (SEC Form 4)

Recent Analyst Ratings for
$AKRO

$AKRO
Insider Trading

$AKRO
Market Insights

$AKRO
Analyst Ratings

$AKRO
Press Releases

$AKRO
SEC Filings

$AKRO
Large Ownership Changes

$AKRO
Financials

$AKRO
Leadership Updates

$AKRO
Insider Purchases